Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2012 by Cepheid.
Recruitment status was Recruiting
AIDS Clinical Trials Group
Information provided by (Responsible Party):
First received: April 24, 2012
Last updated: April 30, 2012
Last verified: April 2012
This observational Mycobacterium tuberculosis (MTB) diagnostics evaluation study is a longitudinal study of pulmonary TB suspects who are undergoing sputum evaluation for pulmonary TB. The sensitivity and specificity of the Xpert MTB/RIF (Mycobacterium tuberculosis/rifampin) assay performed on the first sputum collected for Xpert testing will be compared to gold standard conventional culture methods on two sputum specimens, in HIV-infected and HIV-uninfected participants.
||Observational Model: Cohort
Time Perspective: Prospective
||Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects
Biospecimen Retention: Samples With DNA
Primary Outcome Measures:
- Proportion of all participants with Xpert MTB/RIF Assay MTB positive in sputum #1 who are AFB smear positive and MGIT culture positive for M.tuberculosis. [ Time Frame: Week 0 ] [ Designated as safety issue: No ]
- Proportion of all participants with Xpert MTB/RIF Assay MTB positive in sputum #1 who are AFB smear negative and MGIT culture positive for M.tuberculosis. [ Time Frame: Week 0 ] [ Designated as safety issue: No ]
- Proportion of US participants with Xpert MTB/RIF Assay MTB negative in sputum #1 who are MGIT culture negative for M.tuberculosis. [ Time Frame: Week 0 ] [ Designated as safety issue: No ]
Samples of sputum may be retained
| Estimated Enrollment:
| Study Start Date:
HIV-infected and -uninfected individuals
HIV-infected and -uninfected individuals with suspected TB infection
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
HIV-1-infected and -uninfected men and women, 18 years and older, pulmonary TB suspects who have either a) smear positive sputum or b) clinical suspicion of pulmonary TB including one or more self-reported symptoms of cough, night sweats, weight loss, or fever. Within the 180 days prior to collection of the initial sputum sample, participants will have received none or fewer than 48 hours of TB treatment and, in those 48 hours, fewer than three doses of TB treatment.
- Suspected pulmonary TB (more information on the criterion can be found in the protocol)
- Men and women age equal to or greater than 18 years
- Ability and willingness of candidate or legal guardian/representative to provide informed consent
- Collection of two sputum samples for AFB smear and culture collected within 7 days prior to entry.
- Availability of two samples for Xpert MTB/RIF testing collected within 7 days prior to entry.
- Determination and/or documentation of HIV status
- For HIV-positive candidates, a CD4+ cell count obtained within 45 days prior to study entry or drawn at the time of entry at any laboratory that has a CLIA certification or its equivalent.
- Either receipt of ≥48 cumulative hours OR three or more doses of anti-TB treatment within 180 days prior to completion of second sputum collection for Xpert testing
- Receipt of more than 7 cumulative days of antibiotics intended for bacterial treatment that may have anti-tuberculosis activity, within the 14 days prior to first sputum collection
- Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01587469
|Ucsf Aids Ctu
|San Francisco, California, United States, 94110 |
|Contact: Jay (John) Dwyer email@example.com |
|Principal Investigator: Diane Havlir, MD |
AIDS Clinical Trials Group
||Annie Luetkemeyer, MD
||San Francisco General Hospital
||Cynthia Firnhaber, MD
||University of Witwatersrand, South Africa
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||April 24, 2012
||April 30, 2012
||United States: Institutional Review Board
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on August 21, 2014
Gram-Positive Bacterial Infections
Respiratory Tract Diseases
Respiratory Tract Infections
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors